In the current paper, we showed that B02 potentiate the anti-cancer activity of cisplatin invivo. Our data also demonstrate that B02 inhibits formation of RAD51 foci in tumor tissues in mouse xenografts in response to cisplatin indicating that B02 can be successfully delivered to RAD51 invivo causing cell sensitization through targeted RAD51 inhibition. Here, RAD51 is linked to cancer.